{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:24:39Z","timestamp":1794360279844,"version":"4.9.0"},"reference-count":218,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104989","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T14:44:14Z","timestamp":1761403454000},"page":"104989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Recent findings on the PD-1\/PD-L1 Axis in breast cancer: Molecular mechanisms, immunotherapeutic potentials, and clinical implications"],"prefix":"10.1016","volume":"216","author":[{"given":"Ronak","family":"Ahmadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran Fakhimi","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ommolbanin","family":"Sharmsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7971-4254","authenticated-orcid":false,"given":"Yasin","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar Fakhimi","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Koochehloghmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moein","family":"Hoseinpourfeyzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"45","key":"10.1016\/j.critrevonc.2025.104989_bib1","doi-asserted-by":"crossref","first-page":"22609","DOI":"10.1073\/pnas.1903765116","article-title":"DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation","volume":"116","author":"Abbotts","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22826","article-title":"Association of the study between LncRNA-H19 gene polymorphisms with the risk of breast cancer","volume":"33","author":"Abdollahzadeh","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamaoncol.2018.5152","article-title":"Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial","volume":"5","author":"Adams","year":"2019","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/1078-0432.CCR-21-2182","article-title":"A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual Anti\u2013CTLA-4 and Anti\u2013PD-1 blockade in rare tumors (DART, SWOG S1609)","volume":"28","author":"Adams","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104989_bib5","doi-asserted-by":"crossref","unstructured":"Admoun C., Mayrovitz H.N. The Etiology of Breast Cancer. 2022.","DOI":"10.36255\/exon-publications-breast-cancer-etiology"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104989_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011432","article-title":"Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study","volume":"13","author":"Ahmed","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104989_bib7","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jamaoncol.2022.2310","article-title":"Response rate and safety of a neoadjuvant pertuzumab, atezolizumab, docetaxel, and trastuzumab regimen for patients with ERBB2-positive stage II\/III breast cancer: the neo-PATH phase 2 nonrandomized clinical trial","volume":"8","author":"Ahn","year":"2022","journal-title":"JAMA Oncol."},{"issue":"s1","key":"10.1016\/j.critrevonc.2025.104989_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3747\/co.25.3752","article-title":"Overcoming endocrine resistance in hormone receptor\u2013positive breast cancer","volume":"25","author":"AlFakeeh","year":"2018","journal-title":"Curr. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104989_bib9","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andr\u00e9","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007990","article-title":"Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial","volume":"12","author":"Andresen","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104989_bib11","first-page":"9","article-title":"Male breast cancer: treatment trends, reported outcomes, and suggested recommendations","volume":"13","author":"Arzanova","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.critrevonc.2025.104989_bib12","series-title":"The Epidemiology of Breast Cancer","first-page":"1","author":"Arzanova","year":"2022"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13058-018-1004-0","article-title":"The association of genomic lesions and PD-1\/PD-L1 expression in resected triple-negative breast cancers","volume":"20","author":"Barrett","year":"2018","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41523-021-00287-9","article-title":"Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study","volume":"7","author":"Barroso-Sousa","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib15","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1038\/s41467-025-59695-1","article-title":"Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)","volume":"16","author":"Barroso-Sousa","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.critrevonc.2007.09.001","article-title":"Impact of aging on the biology of breast cancer","volume":"66","author":"Benz","year":"2008","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104989_bib17","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.18632\/oncotarget.7235","article-title":"Activation of the PD-1\/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis","volume":"7","author":"Black","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104989_bib18","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1634\/theoncologist.2010-0035","article-title":"Trastuzumab","volume":"16","author":"Boekhout","year":"2011","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104989_bib19","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti\u2013PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-017-4325-2","article-title":"Family history and risk of breast cancer: an analysis accounting for family structure","volume":"165","author":"Brewer","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104989_bib21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.annonc.2021.01.065","article-title":"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis","volume":"32","author":"Brufsky","year":"2021","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104989_bib22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.breast.2014.08.009","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)","volume":"23","author":"Cardoso","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2025.104989_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2017.01.017","article-title":"The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership","volume":"111","author":"Chajon","year":"2017","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104989_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011314","article-title":"Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial","volume":"13","author":"Chen","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104989_bib25","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1080\/21645515.2020.1840254","article-title":"Effect of radiotherapy on T cell and PD-1\/PD-L1 blocking therapy in tumor microenvironment","volume":"17","author":"Chen","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104989_bib26","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3389\/fimmu.2020.01088","article-title":"Looking for the optimal PD-1\/PD-L1 inhibitor in cancer treatment: a comparison in basic structure, function, and clinical practice","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104989_bib27","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1634\/theoncologist.2019-0321","article-title":"A phase Ib trial of durvalumab in combination with trastuzumab in HER2-positive metastatic breast cancer (CCTG IND. 229)","volume":"24","author":"Chia","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab003","article-title":"Top1-PARP1 association and beyond: from DNA topology to break repair","volume":"3","author":"Chowdhuri","year":"2021","journal-title":"NAR Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib29","first-page":"8","article-title":"Anti-PD-1 and anti-PD-L1 antibodies as immunotherapy against cancer: A structural perspective","volume":"73","author":"C\u00f3rdova-Bahena","year":"2021","journal-title":"Rev. De. Invest\u00f3m. Cl\u00ednica"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104989_bib30","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.ejca.2008.09.013","article-title":"Her2-positive breast cancer: herceptin and beyond","volume":"44","author":"Dean-Colomb","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40425-016-0190-5","article-title":"A New VISTA on combination therapy for negative checkpoint regulator blockade","volume":"4","author":"Deng","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104989_bib35","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","article-title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","volume":"35","author":"Dent","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib37","first-page":"31","article-title":"Breast cancer statistics, 2015: convergence of incidence rates between black and white women","volume":"66","author":"DeSantis","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104989_bib38","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104989_bib39","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002084","article-title":"Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4\/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer","volume":"9","author":"Egelston","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104989_bib42","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104989_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr1020","article-title":"Clinical utility of serum HER2\/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies","volume":"7","author":"Esteva","year":"2005","journal-title":"Breast Cancer Res."},{"issue":"01","key":"10.1016\/j.critrevonc.2025.104989_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cpt.2024.01.001","article-title":"Despicable role of epithelial\u2013mesenchymal transition in breast cancer metastasis: Exhibiting de novo restorative regimens","volume":"3","author":"Famta","year":"2025","journal-title":"Cancer Pathog. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104989_bib45","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","article-title":"Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy","volume":"35","author":"Fang","year":"2019","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes Dis."},{"key":"10.1016\/j.critrevonc.2025.104989_bib47","unstructured":"Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Pi\u00f1eros M., et al. Global cancer observatory: cancer today. International Agency for Research on Cancer. Lyon, France. 2020."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.breast.2013.11.011","article-title":"Treatment of HER2-positive breast cancer","volume":"23","author":"Figueroa-Magalh\u00e3es","year":"2014","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13104-023-06343-w","article-title":"Identification and validation of miR-583 and mir-877-5p as biomarkers in patients with breast cancer: An integrated experimental and bioinformatics research","volume":"16","author":"Foruzandeh","year":"2023","journal-title":"BMC Res. Notes"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104989_bib50","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104989_bib51","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104989_bib52","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41416-023-02349-0","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial","volume":"129","author":"Friedlander","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/jcb.70010","article-title":"Effects of Melatonin on the Expression of Invasion-Related Markers (MMP2 and MMP9) in Breast Cancer Cells","volume":"126","author":"Ghadimi","year":"2025","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.critrevonc.2025.104989_bib54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymeth.2025.04.001","article-title":"Transforming breast cancer diagnosis and treatment with large language Models: a comprehensive survey","volume":"239","author":"Ghorbian","year":"2025","journal-title":"Methods"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104989_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22427","article-title":"Usefulness of machine learning and deep learning approaches in screening and early detection of breast cancer","volume":"9","author":"Ghorbian","year":"2023","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib56","doi-asserted-by":"crossref","DOI":"10.5812\/gct.80166","article-title":"Association of genetic variations in XRCC1 and ERCC1 genes with sporadic breast cancer","volume":"5","author":"Ghorbian","year":"2018","journal-title":"Gene Cell Tissue"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104989_bib57","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104989_bib58","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1158\/1078-0432.CCR-24-1161","article-title":"A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer","volume":"30","author":"Giordano","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"7668","key":"10.1016\/j.critrevonc.2025.104989_bib59","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104989_bib60","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104989_bib61","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/1535-7163.MCT-10-1089","article-title":"PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer","volume":"10","author":"Gonzalez-Angulo","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104989_bib62","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","article-title":"The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy","volume":"33","author":"Gopalakrishnan","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/13543784.2015.991819","article-title":"Nivolumab for the treatment of cancer","volume":"24","author":"Gunturi","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.critrevonc.2025.104989_bib64","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3389\/fimmu.2020.01508","article-title":"Clinical and recent patents applications of PD-1\/PD-L1 targeting immunotherapy in cancer treatment\u2014current progress, strategy, and future perspective","volume":"11","author":"Guo","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib65","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4049\/jimmunol.1200563","article-title":"Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation","volume":"189","author":"Gupta","year":"2012","journal-title":"J. Immunol."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104989_bib66","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104989_bib67","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.clbc.2021.04.011","article-title":"Impact of Anti-HER2 treatments combined with atezolizumab on the tumor immune microenvironment in early or metastatic breast cancer: results from a phase Ib study","volume":"21","author":"Hamilton","year":"2021","journal-title":"Clin. Breast Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib68","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13058-024-01839-0","article-title":"Association of early menarche with breast tumor molecular features and recurrence","volume":"26","author":"Harris","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104989_bib69","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.trac.2017.04.006","article-title":"Early stage screening of breast cancer using electrochemical biomarker detection","volume":"91","author":"Hasanzadeh","year":"2017","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.critrevonc.2025.104989_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.humgen.2024.201343","article-title":"Validation of gene polymorphisms (rs2682818 and rs2043556) in has-miR-618 and has-miR-605 with the breast cancer susceptibility","volume":"42","author":"Hassani","year":"2024","journal-title":"Hum. Gene"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100884","article-title":"Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases","volume":"8","author":"Hecht","year":"2023","journal-title":"ESMO Open"},{"issue":"7528","key":"10.1016\/j.critrevonc.2025.104989_bib72","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-016-3848-2","article-title":"Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies","volume":"158","author":"Hida","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104989_bib74","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104989_bib75","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs\u2014from CTLA4 to PD1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104989_bib76","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in breast cancer survival by molecular subtypes in the United States","volume":"27","author":"Howlader","year":"2018","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104989_bib77","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-019-0400-7","article-title":"Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression","volume":"20","author":"Hu","year":"2019","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104989_bib78","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-21-3435","article-title":"Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for patients with hormone receptor\u2013positive and HER2-positive metastatic breast cancer (SYSUCC-002)","volume":"28","author":"Hua","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib79","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3892\/ijo.2015.3084","article-title":"Epithelial-mesenchymal transition and drug resistance in breast cancer","volume":"47","author":"Huang","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104989_bib80","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.21.02772","article-title":"Atezolizumab with neoadjuvant anti\u2013human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2\u2013positive early breast cancer: primary results of the randomized phase III IMpassion050 trial","volume":"40","author":"Huober","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104989_bib81","series-title":"Seminars in Oncology","article-title":"editors. PD-L1 blockade for cancer treatment: MEDI4736","author":"Ibrahim","year":"2015"},{"key":"10.1016\/j.critrevonc.2025.104989_bib82","unstructured":"Inc G. TECENTRIQ\u00ae(atezolizumab)[package insert]. Genentech, Inc South San Francisco, CA; 2019."},{"key":"10.1016\/j.critrevonc.2025.104989_bib83","unstructured":"Jaleel T.I. Hormone Receptors and Breast Cancer. 1993."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104989_bib84","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.3390\/biomedicines10123154","article-title":"The high-resolution structure reveals remarkable similarity in PD-1 binding of cemiplimab and dostarlimab, the FDA-approved antibodies for cancer immunotherapy","volume":"10","author":"Jeong","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2025.104989_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2023.103580","article-title":"Neoadjuvant nivolumab+ palbociclib+ anastrozole for oestrogen receptor-positive\/human epidermal growth factor receptor 2-negative primary breast cancer: results from CheckMate 7A8","volume":"72","author":"Jerusalem","year":"2023","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104989_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6776","article-title":"A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors","volume":"13","author":"Juric","year":"2024","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104989_bib87","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104989_bib88","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.ijrobp.2010.09.034","article-title":"Radiation enhances regulatory T cell representation","volume":"81","author":"Kachikwu","year":"2011","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104989_bib89","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104989_bib90","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2326-6066.CIR-20-0586","article-title":"Hallmarks of resistance to immune-checkpoint inhibitors","volume":"10","author":"Karasarides","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104989_bib91","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1158\/1078-0432.CCR-14-1038","article-title":"Combined inhibition of Wee1 and PARP1\/2 for radiosensitization in pancreatic cancer","volume":"20","author":"Karnak","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104989_bib92","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.drudis.2019.09.001","article-title":"PI3K\/AKT\/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges","volume":"24","author":"Khan","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.critrevonc.2025.104989_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113386","article-title":"Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: a phase IB\/II study (KCSG BR18-16)","volume":"195","author":"Kim","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104989_bib94","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104989_bib95","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/cancers15041320","article-title":"Targeted therapy and mechanisms of drug resistance in breast cancer","volume":"15","author":"Kinnel","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib96","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13058-020-01283-w","article-title":"Association of TILs with clinical parameters, Recurrence Score\u00ae results, and prognosis in patients with early HER2-negative breast cancer (BC)\u2014a translational analysis of the prospective WSG PlanB trial","volume":"22","author":"Kolberg-Liedtke","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib97","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13014-017-0766-3","article-title":"Current controversies in radiotherapy for breast cancer","volume":"12","author":"Krug","year":"2017","journal-title":"Radiat. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104989_bib98","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib99","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT\u2013mTOR pathway in non\u2013small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104989_bib100","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.3390\/cancers13236112","article-title":"NDRG2 expression in breast cancer cells downregulates PD-L1 expression and restores T cell proliferation in tumor-coculture","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104989_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.102050","article-title":"Parity and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis","volume":"75","author":"Li","year":"2021","journal-title":"Cancer Epidemiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib102","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"issue":"44","key":"10.1016\/j.critrevonc.2025.104989_bib103","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307793120","article-title":"A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors","volume":"120","author":"Lin","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2025.104989_bib104","article-title":"Clinical cancer immunotherapy: Current progress and prospects","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104989_bib105","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib106","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104989_bib107","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104989_bib108","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.breast.2016.07.015","article-title":"The genomic landscape of breast cancer and its interaction with host immunity","volume":"29","author":"Luen","year":"2016","journal-title":"Breast"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104989_bib109","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib110","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1038\/s41467-024-46961-x","article-title":"Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study","volume":"15","author":"Lynce","year":"2024","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104989_bib111","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/jclinpath-2021-207517","article-title":"Gene of the month: lymphocyte-activation gene 3 (LAG-3)","volume":"74","author":"Lythgoe","year":"2021","journal-title":"J. Clin. Pathol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104989_bib112","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.7314\/APJCP.2014.15.8.3353","article-title":"Breast cancer: major risk factors and recent developments in treatment","volume":"15","author":"Majeed","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104989_bib113","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s40265-016-0618-8","article-title":"Atezolizumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2025.104989_bib114","series-title":"The Extracellular Matrix and the Tumor Microenvironment","first-page":"197","article-title":"Heparanase: A Paramount Enzyme for Cancer Initiation, Progression, and Metastasis","author":"Masola","year":"2022"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104989_bib115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007126","article-title":"Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)","volume":"11","author":"Masuda","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104989_bib116","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"JNCI J. Nat. Cancer Inst."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib117","first-page":"496","article-title":"Kinetics of serum HER-2\/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy","volume":"109","author":"Mazouni","year":"2007","journal-title":"Cancer Interdisciplin. Int. J. Am. Cancer Soc."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib118","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/cancers7020815","article-title":"Effects of age on the detection and management of breast cancer","volume":"7","author":"McGuire","year":"2015","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104989_bib119","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1096\/fj.09-151464","article-title":"The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications","volume":"24","author":"Melotte","year":"2010","journal-title":"FASEB J."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104989_bib120","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/cancers15071987","article-title":"Emerging targeted therapies for HER2-positive breast cancer","volume":"15","author":"Mercogliano","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib121","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12935-021-02107-3","article-title":"Triple-negative breast cancer: understanding Wnt signaling in drug resistance","volume":"21","author":"Merikhian","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.critrevonc.2025.104989_bib122","doi-asserted-by":"crossref","first-page":"S1147","DOI":"10.1016\/j.annonc.2020.08.2243","article-title":"LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC)\u00b1atezolizumab (atezo) for unresectable locally advanced\/metastatic triple-negative breast cancer (mTNBC)","volume":"31","author":"Miles","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104989_bib123","first-page":"1","article-title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","author":"Mittendorf","year":"2025","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104989_bib124","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2025.104989_bib125","series-title":"Endocrine Metabolic Immune DisordersDrug Targets (Formerly Current Drug TargetsImmune Endocrine Metabolic Disorders)","first-page":"2131","article-title":"The potential of T cell immunoglobulin and mucin-domain containing-3 (Tim-3) in designing novel immunotherapy for bladder cancer","author":"Mohsenzadegan","year":"2021"},{"key":"10.1016\/j.critrevonc.2025.104989_bib126","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/BCTT.S176070","article-title":"Epidemiological characteristics of and risk factors for breast cancer in the world","author":"Momenimovahed","year":"2019","journal-title":"Breast Cancer Targets Ther."},{"key":"10.1016\/j.critrevonc.2025.104989_bib127","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919894105","article-title":"Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer","volume":"11","author":"Montagna","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104989_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2023.215507","article-title":"Beyond cisplatin: new frontiers in metallodrugs for hard-to-treat triple negative breast cancer","volume":"499","author":"Muhammad","year":"2024","journal-title":"Coord. Chem. Rev."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104989_bib129","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.3390\/cancers13092219","article-title":"V-domain Ig suppressor of T cell activation (VISTA) expression is an independent prognostic factor in multiple myeloma","volume":"13","author":"Mutsaers","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104989_bib130","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014how we can rise to the challenge","volume":"8","author":"Nedeljkovi\u0107","year":"2019","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104989_bib131","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial","volume":"30","author":"Nederlof","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104989_bib132","doi-asserted-by":"crossref","first-page":"S1206","DOI":"10.1016\/j.annonc.2024.08.2249","article-title":"LBA11 Neoadjuvant nivolumab\/relatlimab or nivolumab\/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)","volume":"35","author":"Nederlof","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib133","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010013","article-title":"Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors","volume":"13","author":"Nelson","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104989_bib134","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/2767-9764.CRC-23-0145","article-title":"A pilot study of neoadjuvant nivolumab, ipilimumab, and intralesional oncolytic virotherapy for HER2-negative breast cancer","volume":"3","author":"Nguyen","year":"2023","journal-title":"Cancer Res. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib135","first-page":"291","article-title":"Correlation between Lsp1 (Rs3817198) and Casc (Rs4784227) polymorphisms and the susceptibility to breast cancer","volume":"9","author":"Nourolahzadeh","year":"2020","journal-title":"Rep. Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib136","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40487-023-00224-9","article-title":"Immune checkpoint inhibitors in breast cancer: a narrative review","volume":"11","author":"Nunes Filho","year":"2023","journal-title":"Oncol. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib137","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036905","article-title":"Breast cancer: a review of risk factors and diagnosis","volume":"103","author":"Obeagu","year":"2024","journal-title":"Medicine"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104989_bib138","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1158\/1078-0432.CCR-10-1533","article-title":"Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study","volume":"16","author":"O'Brien","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104989_bib139","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009160","article-title":"Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment","volume":"12","author":"O'Connell","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104989_bib140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2022.05.014","article-title":"Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)","volume":"171","author":"Ozaki","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib141","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.breast.2011.07.008","article-title":"Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry","volume":"21","author":"Park","year":"2012","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib142","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.bbrc.2007.08.195","article-title":"SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells","volume":"363","author":"Park","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib143","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib144","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/1541-7786.MCR-17-0455","article-title":"PARP1 trapping and DNA replication stress enhance radiosensitization with combined WEE1 and PARP inhibitors","volume":"16","author":"Parsels","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104989_bib145","unstructured":"Part D.E. Preliminary safety, efficacy and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1\/CTLA4) from a first-in-human study in subjects with advanced solid tumors. 2019."},{"key":"10.1016\/j.critrevonc.2025.104989_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1296341","article-title":"PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment","volume":"14","author":"Parvez","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104989_bib147","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ctrv.2017.12.008","article-title":"Checkpoint inhibitors in breast cancer\u2013current status","volume":"63","author":"Polk","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104989_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2025.03.012","article-title":"Study on heparanase promoting breast cancer cell proliferation and inhibiting NK cell cytolytic activity via the PD-1\/PD-L1 pathway","author":"Qiu","year":"2025","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2025.104989_bib149","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fendo.2019.00245","article-title":"Endocrine resistance in hormone receptor positive breast cancer\u2013from mechanism to therapy","volume":"10","author":"Rani","year":"2019","journal-title":"Front. Endocrinol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104989_bib150","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib151","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14737140.2020.1732211","article-title":"Atezolizumab for the treatment of breast cancer","volume":"20","author":"Reddy","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104989_bib152","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/1758834015608993","article-title":"Optimal management of hormone receptor positive metastatic breast cancer in 2016","volume":"7","author":"Reinert","year":"2015","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib153","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s43018-024-00890-2","article-title":"Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52\/ATHENE trial","volume":"6","author":"Rinnerthaler","year":"2025","journal-title":"Nat. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104989_bib154","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1038\/s41591-022-02126-1","article-title":"Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial","volume":"28","author":"R\u00f8ssevold","year":"2022","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104989_bib155","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s43018-024-00729-w","article-title":"Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial","volume":"5","author":"Roussos Torres","year":"2024","journal-title":"Nat. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104989_bib156","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1158\/0008-5472-CAN-04-3913","article-title":"PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma","volume":"65","author":"Saal","year":"2005","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib157","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/med.21765","article-title":"Understanding the tumor microenvironment for effective immunotherapy","volume":"41","author":"Sadeghi Rad","year":"2021","journal-title":"Med. Res. Rev."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104989_bib158","first-page":"1124","article-title":"Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)","volume":"52","author":"Saji","year":"2022","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib159","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"issue":"27","key":"10.1016\/j.critrevonc.2025.104989_bib160","doi-asserted-by":"crossref","first-page":"18985","DOI":"10.18632\/oncotarget.24867","article-title":"A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer","volume":"9","author":"Santa-Maria","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib161","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41467-022-30898-0","article-title":"Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor","volume":"13","author":"Scabia","year":"2022","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104989_bib162","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104989_bib163","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1158\/1078-0432.CCR-23-2084","article-title":"First-line ipatasertib, atezolizumab, and taxane triplet for metastatic triple-negative breast cancer: clinical and biomarker results","volume":"30","author":"Schmid","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"36","key":"10.1016\/j.critrevonc.2025.104989_bib164","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104989_bib165","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104989_bib166","series-title":"1st International Integrative Conference on Health, Life and Social Sciences (ICHLaS 2017)","article-title":"editors. Mitotic Index In Invasive Ductal Carcinoma Nst (IDC-Nst) of Breast and Its Relation With Tumor Size and Regional Lymph Nodes Status","author":"Setyaningrum","year":"2017"},{"key":"10.1016\/j.critrevonc.2025.104989_bib167","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s12282-018-00941-4","article-title":"Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development, 1990\u20132016: evidence from Global Burden of Disease Study 2016","volume":"26","author":"Sharma","year":"2019","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib168","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12935-023-03116-0","article-title":"VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy","volume":"23","author":"Shekari","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib169","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104989_bib170","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104989_bib171","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib172","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088557","article-title":"PD-L1 expression is increased in a subset of basal type breast cancer cells","volume":"9","author":"Soliman","year":"2014","journal-title":"PloS One"},{"issue":"02","key":"10.1016\/j.critrevonc.2025.104989_bib173","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-0043-1761942","article-title":"A clinicopathological analysis of molecular subtypes of breast cancer using immunohistochemical surrogates: a 6-year institutional experience from a tertiary cancer center in north India","volume":"12","author":"Somal","year":"2023","journal-title":"South Asian J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib174","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12716","article-title":"T-cell Immunoglobulin and ITIM Domain Contributes to CD 8+ T-cell Immunosenescence","volume":"17","author":"Song","year":"2018","journal-title":"Aging Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","article-title":"An update on PARP inhibitors\u2014moving to the adjuvant setting","volume":"12","author":"Sonnenblick","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104989_bib176","doi-asserted-by":"crossref","first-page":"v461","DOI":"10.1093\/annonc\/mdx380.002","article-title":"Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)","volume":"28","author":"Spigel","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib177","doi-asserted-by":"crossref","first-page":"24","DOI":"10.36401\/JIPO-23-14","article-title":"Oral toxicities associated with immune checkpoint inhibitors: meta-analyses of clinical trials","volume":"7","author":"Srivastava","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib178","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomark. Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104989_bib179","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.7150\/ijbs.21635","article-title":"Risk factors and preventions of breast cancer","volume":"13","author":"Sun","year":"2017","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib180","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-27048-3","article-title":"Phase Ib\/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer","volume":"12","author":"Takada","year":"2022","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104989_bib181","doi-asserted-by":"crossref","first-page":"806","DOI":"10.5858\/arpa.2015-0133-RA","article-title":"Immunohistochemical surrogates for molecular classification of breast carcinoma: a 2015 update","volume":"140","author":"Tang","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104989_bib182","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.3390\/cancers15184522","article-title":"Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies","volume":"15","author":"Tapia","year":"2023","journal-title":"Cancers"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104989_bib183","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1158\/0008-5472.CAN-17-2210","article-title":"Combined CDK4\/6 and PI3K\u03b1 inhibition is synergistic and immunogenic in triple-negative breast cancer","volume":"77","author":"Teo","year":"2017","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib184","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clon.2008.11.006","article-title":"How age affects the biology of breast cancer","volume":"21","author":"Thomas","year":"2009","journal-title":"Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41388-019-0971-7","article-title":"Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1","volume":"39","author":"Timaner","year":"2020","journal-title":"Oncogene"},{"issue":"6477","key":"10.1016\/j.critrevonc.2025.104989_bib186","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104989_bib187","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor\u2013positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"7547","key":"10.1016\/j.critrevonc.2025.104989_bib188","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104989_bib189","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104989_bib190","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s43018-023-00542-x","article-title":"PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial","volume":"4","author":"Voorwerk","year":"2023","journal-title":"Nat. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104989_bib191","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104989_bib192","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.critrevonc.2025.104989_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154791","article-title":"Hormone receptors in breast cancer: An update on the uncommon subtypes","volume":"250","author":"Wei","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib194","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molonc.2010.04.004","article-title":"Histological types of breast cancer: how special are they?","volume":"4","author":"Weigelt","year":"2010","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104989_bib195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.799957","article-title":"The research progress of PD-1\/PD-L1 inhibitors enhancing radiotherapy efficacy","volume":"11","author":"Wen","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib196","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/path.2974","article-title":"Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers","volume":"226","author":"Wetterskog","year":"2012","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib197","first-page":"271","article-title":"Immune checkpoint inhibitor therapy","volume":"23","author":"Wood","year":"2019","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.critrevonc.2025.104989_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2022.106314","article-title":"YB-1 promotes cell proliferation and metastasis by targeting cell-intrinsic PD-1\/PD-L1 pathway in breast cancer","volume":"153","author":"Wu","year":"2022","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.critrevonc.2025.104989_bib199","article-title":"Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib200","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41597-023-02253-5","article-title":"Global trends and forecasts of breast cancer incidence and deaths","volume":"10","author":"Xu","year":"2023","journal-title":"Sci. data"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104989_bib201","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/cmi.2017.148","article-title":"The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation","volume":"15","author":"Xu","year":"2018","journal-title":"Cell. Mol. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104989_bib202","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib203","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-023-06929-9","article-title":"A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer","volume":"199","author":"Yam","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104989_bib204","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajoms.2020.07.018","article-title":"A case of oral lichenoid reaction during nivolumab therapy","volume":"32","author":"Yamanaka","year":"2020","journal-title":"J. Oral. Maxillofac. Surg. Med. Pathol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104989_bib205","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4236\/abcr.2025.141001","article-title":"Understanding Breast Cancer: A Comprehensive Review of Epidemiology, Risk Factors, and Treatment Strategies","volume":"14","author":"Yara","year":"2025","journal-title":"Adv. Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104989_bib207","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.926353","article-title":"Heparanase in cancer progression: Structure, substrate recognition and therapeutic potential","volume":"10","author":"Yuan","year":"2022","journal-title":"Front. Chem."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104989_bib208","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1093\/oncolo\/oyad026","article-title":"Phase I trial of ipatasertib plus carboplatin, carboplatin\/paclitaxel, or capecitabine and atezolizumab in metastatic triple-negative breast cancer","volume":"28","author":"Yuan","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2025.104989_bib209","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.658488","article-title":"Terminating cancer by blocking VISTA as a novel immunotherapy: Hasta la vista, baby","volume":"11","author":"Yum","year":"2021","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104989_bib210","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib211","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(24)00757-5","article-title":"Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902\/IBCSG 61\u201320; Neo-N): a non-comparative, open-label, randomised, phase 2 trial","volume":"26","author":"Zdenkowski","year":"2025","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104989_bib212","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","article-title":"PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Breast Cancer"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104989_bib213","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.7150\/thno.44871","article-title":"CDK4\/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104989_bib214","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1074-7613(04)00051-2","article-title":"Structural and functional analysis of the costimulatory receptor programmed death-1","volume":"20","author":"Zhang","year":"2004","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104989_bib215","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41392-025-02254-3","article-title":"Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin\/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104989_bib216","doi-asserted-by":"crossref","DOI":"10.21037\/apm-21-2062","article-title":"A narrative review of combination therapy of PD-1\/PD-L1 blockade with standard approaches for the treatment of breast cancer: clinical application and immune mechanism","volume":"10","author":"Zhu","year":"2021","journal-title":"Ann. Palliat. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104989_bib217","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"328","key":"10.1016\/j.critrevonc.2025.104989_bib218","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:17:29Z","timestamp":1767388649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":218,"alternative-id":["S1040842825003774"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104989","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent findings on the PD-1\/PD-L1 Axis in breast cancer: Molecular mechanisms, immunotherapeutic potentials, and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104989"}}